British pharmaceutical firm GSK announced that it would stop selling its blood cancer drug Blenrep in the United States.
The company announced on November 22 that it had begun withdrawing the drug’s marketing authorization in the country.
It clarified, however, that trials for the drug would continue and that some patients would be allowed to enroll themselves for continued access to the treatment.